{"protocolSection":{"identificationModule":{"nctId":"NCT00735839","orgStudyIdInfo":{"id":"V710-006"},"secondaryIdInfos":[{"id":"2008_017"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck S. Aureus Vaccine (V710) in Healthy Male Japanese Subjects"},"statusModule":{"statusVerifiedDate":"2015-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-03"},"primaryCompletionDateStruct":{"date":"2008-06","type":"ACTUAL"},"completionDateStruct":{"date":"2008-06","type":"ACTUAL"},"studyFirstSubmitDate":"2008-08-13","studyFirstSubmitQcDate":"2008-08-13","studyFirstPostDateStruct":{"date":"2008-08-15","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-05-23","resultsFirstSubmitQcDate":"2012-05-23","resultsFirstPostDateStruct":{"date":"2012-06-26","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-12-18","lastUpdatePostDateStruct":{"date":"2015-12-21","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This study is to evaluate the safety and immunogenicity of V710 in Japanese male subjects."},"conditionsModule":{"conditions":["Staphylococcal Infection"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":40,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"V710","type":"EXPERIMENTAL","description":"V710 vaccination (60 mcg) single dose on Day 1","interventionNames":["Biological: V710"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo single dose on Day 1","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"V710","description":"V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1","armGroupLabels":["V710"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Saline placebo (0.5 ml) single injection on Day 1","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Geometric Mean Fold Rise (GMFR) From Baseline in Antibody Level","description":"Geometric mean fold rise is calculated as the natural logarithm of the ratio of Day 14 and baseline antibody titers.","timeFrame":"Baseline (Day 1) to Day 14 postvaccination"},{"measure":"Number of Participants With Vaccine-related Serious Adverse Experiences","description":"Vaccine-related adverse experiences are those determined by the investigator to be possibly, probably, or definitely vaccine-related.","timeFrame":"Baseline (Day 1) to Day 84 postvaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Generally Good Physical Health\n\nExclusion Criteria:\n\n* Received V710 Vaccine, Any Other Investigational S. Aureus Vaccine, Or Investigational S. Aureus Antibodies Before\n* Temperature Of Equal/Greater Than 100.4 Degrees F(38 Degrees C) Within The Past 48 Hours","healthyVolunteers":true,"sex":"MALE","minimumAge":"20 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Monitor","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"V710","description":"V710 vaccination (60 mcg) single dose on Day 1"},{"id":"FG001","title":"Placebo","description":"Placebo single dose on Day 1"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"V710","description":"V710 vaccination (60 mcg) single dose on Day 1"},{"id":"BG001","title":"Placebo","description":"Placebo single dose on Day 1"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"40"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"<20 years","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]},{"title":"20-74 years","categories":[{"measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"40"}]}]},{"title":">74 years","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"30"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"40"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Fold Rise (GMFR) From Baseline in Antibody Level","description":"Geometric mean fold rise is calculated as the natural logarithm of the ratio of Day 14 and baseline antibody titers.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Ratio","timeFrame":"Baseline (Day 1) to Day 14 postvaccination","groups":[{"id":"OG000","title":"V710","description":"V710 vaccination (60 mcg) single dose on Day 1"},{"id":"OG001","title":"Placebo","description":"Placebo single dose on Day 1"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","lowerLimit":"3.0","upperLimit":"6.4"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.8","upperLimit":"1.0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Vaccine-related Serious Adverse Experiences","description":"Vaccine-related adverse experiences are those determined by the investigator to be possibly, probably, or definitely vaccine-related.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Baseline (Day 1) to Day 84 postvaccination","groups":[{"id":"OG000","title":"V710","description":"V710 vaccination (60 mcg) single dose on Day 1"},{"id":"OG001","title":"Placebo","description":"Placebo single dose on Day 1"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Day 1 through Day 14 postvaccination","eventGroups":[{"id":"EG000","title":"V710","description":"V710 vaccination (60 mcg) single dose on Day 1","seriousNumAffected":0,"seriousNumAtRisk":30,"otherNumAffected":12,"otherNumAtRisk":30},{"id":"EG001","title":"Placebo","description":"Placebo single dose on Day 1","seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":2,"otherNumAtRisk":10}],"otherEvents":[{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":30},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Pharyngolaryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (11.0)","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":30},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":10}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D013203","term":"Staphylococcal Infections"}],"ancestors":[{"id":"D016908","term":"Gram-Positive Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"C579630","term":"V710 vaccine"}]}},"hasResults":true}